San Antonio, TX, United States
San Antonio, TX, United States

Time filter

Source Type

MarketStudyReport.com adds “Global Lung Cancer Therapeutics Market 2016-2020” new report to its research database. The report spread across 101 pages with table and figures in it. The Report analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020. About Lung Cancer Therapeutics Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly. Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/global-lung-cancer-therapeutics-market-2016-2020/ The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period. The market is divided into the following segments based on geography:  - Americas - APAC - EMEA The Report Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors  - F. Hofmann-La Roche - Eli Lilly - AstraZeneca - Pfizer - Celgene Other prominent vendors  - Abbvie - Aetna - Agennix - Allergan - Amgen - ARIAD Pharmaceuticals - Astellas Pharma - Betta Pharmaceuticals - BeyondSpring Pharmaceuticals - BioNumerik Pharmaceuticals - Boehringer Ingelheim - Boston Biomedical - Bristol-Myers Squibb - Celldex - CTI BioPharma - Eisai - GlaxoSmithKline - GTx - Helsinn - Hutchison Medipharma - Ionis Pharmaceuticals - Kadmon Corporation - MabVax - Merck - Novartis - NovaRx Corporation - OncoGeneX - Ono Pharmaceutical - OSE Immunotherapeutics - OSI Pharmaceuticals - Peregrine - PharmaMar - Pierre Fabre - Qiagen - Recombio - Samsung Bioepis - Sanofi - SFJ Pharmaceuticals - Spectrum Pharmaceuticals - Sumitomo Dainippon Pharma - Synta - Takeda Pharmaceuticals - Teva Pharmaceutical - Xcovery Market driver  - Growing demand for targeted therapies - For a full, detailed list, view our report  Market challenge  - Growing popularity of alternative therapeutics  - For a full, detailed list, view our report  Market trend  - Emergence of nanomedicine platform for the treatment of lung cancer - For a full, detailed list, view our report  Key questions answered in this report  - What will the market size be in 2020 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? To receive personalized assistance, write to us @ [email protected] with the report title in the subject line along with your questions or call us at +1 866-764-2150


— Market Scenario: Breast cancer begins when cells in the breast start to grow out of control. These cells for the most part frame a tumor that can regularly be seen on an x-beam or felt as a lump. The tumor is dangerous (cancerous) if the cells can develop into (attack) surrounding tissues or spread (metastasize) to far off parts of the body. Segments: By Types o Ductal Carcinoma In Situ o Invasive (Or Infiltrating) Ductal Carcinoma o Inflammatory Breast Cancer o Phyllodes Tumor o Angiosarcoma Key Players • Novartis AG (Switzerland) • Pfizer (US) • OncoGenex Pharmaceuticals Inc. (US) • Astellas Pharma Inc. (Japan) • BioNumerik Pharmaceuticals, Inc. (US) • Cascadian Therapeutics (US) • Merck & Co., Inc. (US) Regional Analysis of Breast cancer Market: Globally North America is the largest market for Breast cancer. The North American market for Breast cancer is expected to grow at a CAGR of XX% and is expected to reach at US$ XXX Million by the end of the forecasted period. This growth is attributed to change in lifestyle which leads to developing cancer. Europe is the second-largest market for Breast cancer which is expected to grow at a CAGR of XX%. Whereas Asia pacific is expected to be a growing market for Breast cancer market and expected to grow at a rapid rate. Taste the market data and market information presented through more than 70 market data tables and figures spread in 115 numbers of pages of the project report. Avail the in-depth table of content TOC & market synopsis on “Global Breast Cancer Market Research Report- Forecast To 2027” Study Objectives of Breast cancer Market:  To provide detailed analysis of the market structure along with forecast for the next 10 years of the various segments and sub-segments of the Breast cancer market  To provide insights about factors affecting the market growth  To analyze the Breast Cancer Market based on various factors- price analysis, supply chain analysis, porters five force analysis etc.  To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.  To provide country level analysis of the market with respect to the current market size and future prospective  To provide country level analysis of the market for segments by type, by treatment types, by end users and its sub-segments  To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market  To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Breast cancer market. Table of Content 1. Report Prologue 2. Introduction 2.1 Definition 2.2 Scope of the Study 2.2.1 Research Objective 2.2.2 Assumptions 2.2.3 Limitations 2.3 Market Structure 2.4. Market Segmentation 3. Research Methodology 3.1 Research Process 3.2 Primary Research 3.3 Secondary Research 3.4 Market Size Estimation 3.5 Forecast Model 4. Market Dynamics 4.1 Drivers 4.2 Restraints 4.3 Opportunities 4.4 Mega Trends 4.5 Macroeconomic Indicators 5. Market Factor Analysis 5.1 Value Chain Analysis 5.2 PORTERS Five Forces 5.3 demand & supply: gap analysis 5.4 Pricing Analysis 5.5 Investment Opportunity Analysis 5.6 Merger and Acquisition Landscape 5.7 UP-Coming trends in Breast cancer market 5.7.1 Market trends 5.7.2 Technological trends 6. Global Breast Cancer Market by type 7. Global Breast cancer market by treatment types 8. Global Breast cancer market by end users 9. Global Breast cancer market by regions 9.1 Introduction 9.2 North America 9.2.1 US 9.2.2 Canada 9.3 Europe 9.3.1 Western Europe 9.3.1.1 Germany 9.3.1.2 France 9.3.1.3 Italy 9.3.1.3 Spain 9.3.1.5 UK 9.3.1.6 Rest of Western Europe 9.3.2 Eastern Europe 9.4 Asia 9.4.1 China 9.4.2 India 9.4.3 Japan 9.4.4 South Korea 9.4.5 Rest of Asia 9.5 Pacific 9.6 Latin America, Middle East & Africa Related Report Global Anal Cancer Market Information, by type (Squamous cell carcinomas, Adenocarcinomas, perianal skin cancers, Melanomas and others), by treatment (chemotherapy, radio therapy, surgery and others), by end users (hospitals, clinics, research institutes and others) - Forecast to 2027 https://www.marketresearchfuture.com/reports/global-anal-cancer-market-research-report-forecast-to-2027 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. For more information, please visit https://www.marketresearchfuture.com/reports/global-breast-cancer-market-research-report-forecast-to-2027


News Article | February 15, 2017
Site: www.marketwired.com

MOUNTAIN VIEW, CA--(Marketwired - February 13, 2017) - Amunix Operating Inc., a privately held biotechnology company and developer of a broad portfolio of biopharmaceuticals based on its novel XTEN® polymer half-life extension technology, XTEN drug-conjugate delivery technology and bispecific T-cell engager (ProTIA) pro-drug cancer therapeutics platforms, announced that it has appointed Frederick Hausheer, MD, FACP, as its Chief Medical Officer. Dr. Hausheer brings more than 25 years' experience in global oncology drug development, translational medicine, and drug discovery in commercial and academic settings to Amunix. Volker Schellenberger, Ph.D., President and Chief Executive Officer, said, "We are extremely pleased to have Fred join the Amunix management team. He brings exceptionally broad product development leadership and clinical expertise to the organization. His deep clinical experience in the oncology field will be especially valuable in the support of our ProTIA oncology platform. I look forward to working with Fred to accelerate the advancement of our clinical pipeline." Dr. Hausheer said, "It is a great privilege to be joining Amunix. I am exceedingly impressed with the technology, the Amunix team and the progress that has been made with the company's ProTIA T-cell engager cancer targeting platform which has broad potential to serve as a novel important therapeutic option over current cancer treatment regimens. I am excited about the prospects for advancing the pipeline of ProTIA platform products into patients and beyond. I believe that Amunix' innovative technologies will be an important advance for immuno-oncology drugs to improve patient outcomes." Over the course of his career, Dr. Hausheer has helped secure over $750 million in financial transactions involving capital raising, joint ventures, strategic alliances and licensing of compounds for partnership opportunities. He is experienced in trial design and execution, and involved in numerous regulatory interactions for drugs spanning from pre-IND and Phase I-III development in the United States, Europe, Asia/PAC and other territories. As founder, Chairman, CEO and President of BioNumerik from 1992-2015, he led the discovery and development of two novel oncologic therapeutics from laboratory through global Phase III development. In addition, he co-founded and served as Chairman of KI Pharma from 2005-2013, a joint venture between BioNumerik Pharmaceuticals, Inc. and ASKA Pharmaceutical Co., with a focus on development and commercialization of oncology products in Japan. Prior to joining industry, Dr. Hausheer was an Associate Professor of Medical Oncology and Associate Director Drug Development and Chief, Molecular Design at the University Texas Health Science Center and Cancer Therapy and Research Center and performed oncology drug research as a Senior Scientist at the National Cancer Institute. Dr. Hausheer completed his graduate training in Physiology and Biophysics at the University of Illinois-Champagne. He obtained his MD and completed his Internal Medicine residency at the University of Missouri School of Medicine, followed by completion of Medical Oncology fellowship training and joining the faculty at Johns Hopkins, where he focused on development of novel experimental therapeutics and pharmacology. He currently holds adjunct professorships at the University of Missouri in Internal Medicine and Oncology and The Johns Hopkins Oncology Center in Medical Oncology. He is board certified in Internal Medicine and Medical Oncology. Dr. Hausheer has published over 200 articles, abstracts and book chapters, and is an inventor or co-inventor on more than 400 issued/allowed United States and international patents. He has served as a board member to JP Morgan Chase, the Whittaker Institute for BioMedical Engineering at Johns Hopkins, the National Cancer Institute's (NCI) Experimental Therapeutics Study Section I, and the NCI Institutional Review Board. Amunix, based in Mountain View, CA, is a privately held biotechnology company focused on the discovery and development of biologics with improved in vivo half-lives. Amunix' half-life extension technology is based on XTEN -- hydrophilic, unstructured, biodegradable proteins that impart a number of favorable properties upon the molecules to which they are attached. XTEN can be recombinantly fused or chemically conjugated to peptides, proteins, and other pharmaceuticals. In addition to the advantages of reduced dosing frequency, XTENylation also stabilizes plasma drug concentrations, which often results in increased efficacy as well as reduced side effects. Two genetically fused XTENylated products have been tested clinically. VRS-859 (exenatide-XTEN) has been tested through Phase I in the treatment of diabetes and VRS-317 (human growth hormone-XTEN) is currently in Phase III testing. Amunix is also working with additional partners, including Eli Lilly, Bioverativ, Roche, Janssen, Naia and other undisclosed companies in a wide range of therapeutic areas. Amunix is developing an internal pipeline of ProTIA (Protease Triggered Immune Activator) immuno-oncology therapeutics. ProTIAs are bispecific molecules that bind tumor antigens and T cells. ProTIAs are administered as long-acting prodrugs that can be activated in the tumor environment by tumor-associated proteases. Amunix is actively seeking partnerships for applications of its XTEN technology and its ProTIA platform. For additional information about the company, please visit www.amunix.com.


Trademark
BioNumerik Pharmaceuticals | Date: 2012-12-25

pharmaceutical preparations, namely, medications used in chemotherapeutic regimens for the treatment of cancer.


The present invention discloses and claims methods and compositions for the treatment of subjects having advanced ovarian cancer, including platinum and/or taxane chemotherapy resistant or refractory sub-populations, with the administration to the subject having advanced ovarian cancer of the silicon-containing highly lipophilic camptothecin derivative (HLCD), Karenitecin (also known as BNP1350; cositecan; 7-[(2-trimethylsilyl)ethyl]-20(S) camptothecin) in an amount sufficient to provide a therapeutic benefit. The administration of Karenitecin by intravenous (i.v.) and/or oral methodologies are also disclosed and claimed. Methods for the administration of Karenitecin to increase Progression Free Survival (PFS) are also disclosed and claimed herein.


The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth aggressiveness of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.


The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth aggressiveness of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients.


Patent
BioNumerik Pharmaceuticals | Date: 2014-05-23

The present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the contemporaneous, heterogeneously-oriented, multi-targeted therapeutic modification and/or modulation of cellular metabolic anomalies or other undesirable physiological conditions, including cancer, where the normal cellular biochemical function and/or the expression levels of various proteins/enzymes (i.e., the target molecules) are abnormal and must be modified and/or modulated in order to treat these metabolic anomalies or other undesirable physiological conditions, including cancer. Administration of the most effective medicinal agent(s) to be administered in combination with the administration of the sulfur-containing, amino acid-specific small molecules is disclosed.


Trademark
BioNumerik Pharmaceuticals | Date: 2012-07-27

Pharmaceutical preparations for use in chemotherapy.


Loading BioNumerik Pharmaceuticals collaborators
Loading BioNumerik Pharmaceuticals collaborators